Argenx reports first quarter 2023 financial results and provides business update

$218 million in first quarter vyvgart® (efgartigimod alfa-fcab) global net product sales vyvgart received marketing authorization in israel through partnership with medison 88 events achieved in adhere trial; topline data now expected in july 2023 enrollment completed in advance-sc and address trials; topline data from both expected in fourth quarter of 2023 management to host conference call today at 2:30 pm cet (8:30 am et) regulated information/inside information may 4 , 202 3 amsterdam , the netherlands – argenx se (euronext & nasdaq: argx), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its first quarter 2023 financial results and provided a business update. “throughout the first quarter, we made significant progress advancing our mission to redefine what well-controlled means in the treatment of autoimmune diseases.
ARGX Ratings Summary
ARGX Quant Ranking